Abstract Uterine serous carcinoma (USC) is an aggressive subtype of endometrial cancer that carries an extremely poor prognosis. Up to 35 % of USC may overexpress the epidermal growth factor receptor-2 (HER2/neu) at strong (i.e., 3+) level by immunohistochemistry (IHC) or harbor HER2/neu gene amplification by fluorescence in situ hybridization (FISH). In this study, we assessed the sensitivity of a panel of USC cell lines with and without HER2/neu gene amplification to dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor tyrosine kinase inhibitor. Eight primary cell lines (i.e., four harboring HER2/neu gene amplification by FISH and four FISH− cell lines), all demonstrating similar in vitro growth rates, were evaluated in viability/proliferation assays. The effect of dacomitinib on cell growth, cell cycle distribution, and signaling was determined using flow cytometry-based assays. Dacomitinib caused a significantly stronger growth inhibition in HER2/neu FISH+ USC cell lines when compared to FISH− USC (dacomitinib half maximal inhibitory concentration (IC 50 ) mean±SEM= 0.02803±0.003355 μM in FISH+ versus 1.498±0.2209 μM in FISH− tumors, P<0.0001). Dacomitinib growth inhibition was associated with a significant and dose-dependent decline in phosphorylated HER2/neu and S6 transcription factor and a dose-dependent and time-dependent cell cycle arrest in G0/G1 in FISH+ USC. Dacomitinib is remarkably effective against chemotherapy-resistant HER2/neu gene-amplified USC. Clinical studies with dacomitinib in HER2/neu FISH+ USC patients resistant to standard salvage chemotherapy are warranted.
31-80 % [5] . Stage by stage, uterine serous carcinoma, compared to endometrioid adenocarcinoma, portends a worse 5-year survival rate [4] [6] . Given the biologically aggressive nature and high recurrence and mortality rates, new treatments are desperately needed for USC patients. Proto-oncogenes are a group of normal genes that play important roles in the regulation of cell proliferation. Abnormalities in the expression, structure, or activity of proto-oncogene products contribute to the development and maintenance of the malignant phenotype. The human HER2/neu (c-erbB2) gene product, like the epidermal growth factor receptor, is a transmembrane receptor protein that includes a cysteine-rich extracellular ligand binding domain, a hydrophobic membrane spanning region, and an intracellular tyrosine kinase domain [7] . With no direct ligand identified to date, HER2/neu functions as a preferred partner for heterodimerization with other members of the epidermal growth factor receptor (EGFR) family (namely HER1 or ErbB1, HER3 or ErbB3, and HER4 or ErbB4) and thus plays an important role in coordinating the complex ErbB signaling network that is responsible for regulating cell growth and differentiation [7] . In recent Gynecologic Oncology Group (GOG) studies (i.e., GOG 177), HER2 overexpression (either 2+ (moderate) or 3+ (strong) by immunostaining) and HER2 gene amplification (a ratio of HER2 copies to chromosome 17 (CEP17) copies>or=2) were detected in 44 % (104 of 234; 58 were 2+ and 46 were 3+) and 12 % (21 of 182) of the endometrial cancer specimens tested, respectively [8] . In these studies, a significant increased frequency of HER2 overexpression was found in USC vs. the other subtypes (23 of 38, 61 % vs. 81 of 196, 41 %, respectively, P=0.03). The results of GOG 177 confirmed previous studies documenting amplification of HER2/neu in 26-62 % of USC cases and suggest HER2/neu as a potential target for novel therapies in this biologically aggressive variant of endometrial cancer [9] . Dacomitinib (PF-00299804) is an oral, irreversible pan-ErbB small molecule tyrosine kinase inhibitor (TKI), currently in clinical trials in patients with advanced non-small cell lung cancer (NSCLC) [10] [11] [12] [13] [14] . Unlike previous HER2-specific compounds, which targeted extracellular receptor domains (i.e., trastuzumab or pertuzumab), dacomitinib works by irreversibly inhibiting the kinase activity of HER1/EGFR, HER2, and HER4 through binding covalently to the receptor tyrosine kinase domains and preventing autophosphorylation, thereby inhibiting downstream signaling and leading to tumor growth inhibition and apoptosis [15] . Our preclinical study represents the first evaluation of dacomitinib against primary HER2/neu-amplified vs. non-amplified USC cell lines in vitro as well as a molecular evaluation of the downstream effects of dacomitinib on the intracellular signaling pathway and cell cycle distribution. This understanding may lead to novel therapies for patients harboring this aggressive and deadly subset of endometrial tumors.
Methods
Collection of tumors, establishment of primary USC cell lines, and assessment of HER2/neu status Patients were consented for tumor banking prior to surgery, and samples of each tumor were collected under approval of the institutional review board (IRB). These tumors were processed such that portions of the tumor were saved for genetic analysis and immunohistochemistry and a portion homogenized and reconstituted in petri dishes to establish primary cell lines. Cell lines were grown and established in a culture medium of RPMI 1640 as described previously [16] . Primary USC cell lines (four with HER2 gene amplification and four without) demonstrating similar in vitro growth rates were selected for analysis.
Drug
Dacomitinib (PF-00299804), an irreversible inhibitor of HER1 (EGFR), HER2, and HER4 tyrosine kinases, was provided by Pfizer Inc. (Peapack, NY). It was diluted to a solution of 10 mM in DMSO (Sigma-Aldrich, St. Louis, MO) to create a stock solution.
Chemo-response assays
The effect of dacomitinib on the half maximal inhibitory concentration (IC 50 ) of cells was determined using flow cytometry assays. Tumor cells of the eight primary USC cell lines were harvested during the exponential growth phase and plated in six-well plates for chemo-response assays. HER2-amplified and non-amplified cell lines were grown in a monolayer at the starting concentration of 15,000 cells/ml using RPMI 1640 with 10 % FBS and 1 % penicillin streptomycin and 1 % amphotericin B. After 24 h of incubation, the cells were treated with scalar concentrations of dacomitinib ranging from 0.001 to 2 μM for 72 h. Concentrations up to 4.0 μM were used against the more resistant USC cell lines in additional experiments. At the 72-h time point, the entirety of the samples were collected and centrifuged. The effect on cell viability was determined by staining each sample with propidium iodide (PI) (2 μl of 500 μg/ml stock solution in phosphate-buffered saline (PBS) with 1 % azide and 2 % fetal bovine serum, Biotium) and reading it using the FACSCalibur flow cytometry platform (Becton, Dickinson & Company, San Jose, CA). This allowed for quantification of the percent viable cells as a mean±SEM relative to vehicle-treated cells as 100 % viable controls. The IC 50 for each cell line was then calculated using GraphPad Prism 6 (GraphPad Software, Inc., San Diego, CA). Each experiment was repeated a minimum of three times per cell line.
Cell cycle analysis
Cells were plated in six-well plates at a concentration of 20, 000 cells/ml. They were allowed to incubate for 24 h. Scalar amounts of dacomitinib were then placed in each well. Cultures were allowed to incubate for up to 48 h and harvested at the time point of 12, 24, and 48 h for analysis. Cells were stained as previously described [17] . Data were analyzed using FlowJo software (FlowJo X 10.0.7, Ashland, OR).
HER2/neu and S6 phosphorylation
Cells were plated at 100,000 cells/ml of RPMI into six-well plates. They were allowed to incubate for 24 h. Cells were then treated with dacomitinib at concentrations of 0.010, 0.120, and 0.240 μM. After incubation for 2, 4, 8, 10, 12, 16, and 24 h, they were harvested. Cells were fixed using 4 % paraformaldehyde for 10 min at 37°C and then washed with PBS and permeabilized with 90 % methanol for more than 30 min. They were suspended in incubation buffer (PBS containing 0.5 % BSA), blocked for 10 min, and aliquoted into three tubes. Cells were allowed to incubate with primary rabbit monoclonal antibodies, Phospho-HER2/ErbB2 (Y1221/1222 Cell Signaling Technologies, Inc., Danvers, MA) and Phospho-S6 Ribosomal Protein (Ser235/236 Cell Signaling Technology, Inc., Danvers, MA), and no primary antibody for 1 h on ice. Cells were then washed in incubation buffer two times and allowed to incubate with fluoresceinconjugated goat anti-rabbit immunoglobulin (AQ132F) secondary fluorescein-conjugated antibody (Millipore, Temecula, CA) for half an hour on ice. Samples were then washed, suspended in PBS, and read by flow cytometry. Mean fluorescent intensities (MFI) were then calculated using FlowJo software. The difference in MFI between groups and treatments were then compared.
Statistical analysis
Statistical analysis was completed using GraphPad Prism 6 (GraphPad Software, Inc., San Diego, CA). All data in different experimental groups were expressed as the mean±SEM. Data shown in the study were obtained from at least three independent experiments. All IC 50 data were analyzed by first normalizing the number of live cells in each well treated with drug to the number of live cells in the untreated control. Using Prism 6, normalized data were fit to nonlinear three-parameter logistic dose-response curves against the base-10 logarithms of dose in micromolar. The resulting parameter estimates were used to calculate the IC 50 in log 10 units for each experiment. One-way analysis of variance was used to compare the IC 50 data of HER2-amplified vs. non-amplified cell lines, while group means were compared using Student's t test. Unpaired two-sided Student's t tests were used to compare the cell cycle changes after removal from the analysis of the aggregates of apoptotic/dead tumor cells (i.e., sub-G1 phase) as well as the differences in the mean fluorescent intensities (MFI) pHER2 and pS6. Two-way ANOVA test was used for multiple comparisons of the MFI changes in phosphoprotein pHER2 and pS6 levels before and after the exposure to dacomitinib. Differences in all comparisons were considered statistically significant if P<0.05. The significance of difference is indicated as *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001.
Results

Selection of cell lines and determination of sensitivity to dacomitinib
Cell lines were selected based on differential expression of HER2/neu detected by immunohistochemistry (IHC) and confirmed by FISH analysis based upon our previously published data [16, 18] . Four of the fifteen established cell lines that showed amplification of HER2/neu were selected as experimental cell lines because of their similar growth rates [16] . Four more cell lines that were not HER2/neu amplified were selected as controls. The characteristics of the cell lines and patient's tumors from which they were established are described in Table 1 . First, we evaluated the cell line response to dacomitinib in viability/proliferation flow cytometry-based assays. As representatively shown in Fig. 1a , we found dacomitinib to cause a significantly stronger differential growth inhibition in FISH+ USC cell lines when compared to FISH−. For example, FISH+ cell lines, ARK-2, and ARK-21, were the most sensitive to dacomitinib, with a mean inhibitory concentration (IC 50 )±standard error of mean (SEM) of 0.01153±0.00130 and 0.02687±0.00360 μM, respectively. Within the FISH− cell lines, ARK-7 and ARK-22 were found to be the least sensitive, with IC 50 values of 1.58000±0.19720 and 2.629±0.05258 μM, respectively (Fig. 1a) . Final analysis of FISH+ cell lines revealed that they were more than 50-fold more sensitive to dacomitinib in vitro than their non-amplified counterpart (dacomitinib IC 50 mean ± SEM = 0.02803 ± 0.003355 μM in c-erbB2 amplified versus 1.498 ± 0.2209 μM in c-erbB2 not amplified tumors, P<0.0001, Fig. 1b) . These data suggest that uterine serous carcinoma cell lines that overexpress HER2/neu are exquisitely sensitive to dacomitinib in vitro.
Alterations in cell cycle distribution with dacomitinib treatment
The effect of dacomitinib on HER2-amplified uterine serous carcinoma cell lines in vitro was further examined through cell cycle analysis by PI staining. As shown in Fig. 2a , treatment with dacomitinib induced G0/G1 cell cycle arrest in HER2-amplified cell lines in dose-dependent and time-dependent manners. As representatively shown for ARK-2 cells in (Fig. 2b) . When ARK-2 cells were incubated with 0.140 μM of dacomitinib for a different time course (i.e., from 12 to 48 h), the percentage of USC cells arrested in G0/ G1 significantly increased from 37.76 % in the untreated control to 43.40 % (P = 0.0037), 45.69 % (P < 0.0001), and 46.20 % (P = 0.0024) at 12, 24, and 48 h, respectively (Fig. 2c) . As representatively demonstrated for ARK-11 in Fig. 3c , no such effect was observed in any of the HER2-tested FISH− USC cell lines. These results suggest that dacomitinib may potently inhibit the rapid progression through the cell cycle of HER2-amplified cell lines.
Alterations in HER2/neu and S6 phosphorylation after treatment with dacomitinib
The USC cell line ARK-2 was chosen as the representative HER2-amplified cell line while ARK-11 was chosen as the non-amplified control cell line due to their differential expression of HER2/neu and nearly identical doubling time (ARK-2 vs. ARK-11, 18.2 vs. 23.1 h, data not shown). In experiments performed at different time points, we found a clear effect of dacomitinib on the phosphorylation of HER2 and S6 after 8-h exposure in the HER2-amplified cell lines (i.e., ARK-2) but not in the FISH− cell line (i.e., ARK-11) using 0.010 μM of dacomitinib. Thus, 8 h was selected as the initial time point for the analysis of changes in HER2 and S6 phosphorylation. These experiments were replicated in ARK-2 using doses of dacomitinib based on data regarding C trough (the human serum concentration prior to dose administration at steady state, approximately 0.140 μM) and C max (the maximum plasma concentration, approximately 0.240 μM), achieved in humans after cycle 1 day 7 and multiple dosing of 45 mg of dacomitinib daily [19] ; these values were consistent with those previously reported [20, 21] . Time course experiments were first performed using 0.140 μM of dacomitinib. Data revealed that there was a decrease in the phosphorylation of HER2 and S6 with the time course extension while reaching its nadir at 16 h (Fig. 3a, b) . Furthermore, a dose-response assay was then completed at the 8-h time point using the IC 50 of the two cell lines and C trough and C max in humans after cycle 1 day 7 and multiple dosing of 45 mg of dacomitinib Fig. 3d) . However, while a decrease in phosphorylation of HER2 and S6 was detected after the exposure to dacomitinib in HER2-non-amplified cell line ARK-11, there was no significant difference in all the MFI for HER2 and S6 with 0.010, 0.140, or 0.240 μM when compared with the untreated cells.
Further analysis using a two-way ANOVA accounting for both HER2 amplification status and dacomitinib treatment found that HER2-amplified cell line ARK-2 showed a significant decrease in HER2 and S6 phosphorylation (P<0.0001) compared with the nonamplified USC cell line ARK-11 after treatment with dacomitinib. Similar results were obtained using the remaining USC amplified vs. non-amplified control cell lines (data not shown). These data suggest that tumors reliant upon HER2 amplification as a driver for proliferation are indeed susceptible to treatment with dacomitinib in vitro.
Discussion
Development of novel effective therapies against recurrent chemotherapy-resistant USC remains an unmet medical need. Although recent comprehensive genetic studies (i.e., wholeexome sequencing) from The Cancer Genome Atlas (TCGA) Network and our own research group have reported that 21 to 44 % of USC may harbor HER2/neu gene amplifications [18, 22] and this is associated with aggressive disease and poor prognosis in multiple human tumors including USC [23] [24] [25] [26] , currently, no FDA-approved drugs are available for the treatment of endometrial cancer patients harboring chemotherapy-resistant/recurrent disease overexpressing HER2/neu. Trastuzumab is a humanized anti-HER2/neu MAb endowed with significant clinical activity in HER2-amplified breast cancer patients [27, 28] . However, despite encouraging case reports [29] [30] [31] , when trastuzumab was evaluated as a singleagent by the GOG in a heterogeneous group of endometrial cancer patients overexpressing HER2/neu (i.e., GOG-181B), it failed to demonstrate significant activity [28] . While ongoing clinical trials are assessing the efficacy of trastuzumab in combination with chemotherapy in a more homogenous group of patients with HER2/neu-amplified USC (i.e., NCT01367002), certain characteristics of irreversible panerbB receptor tyrosine kinase inhibitors, such as dacomitinib, suggest potential higher clinical activity against USC. For example, reports in breast cancer have shown that trastuzumab may bind intermittently with HER2 or with less affinity due to receptor conformational variants [32] . These interactions lead to inhibition of signaling through the HER2 pathway but are potentially less efficient at inhibiting proliferation pathways than might be expected in HER2-amplified tumors. Moreover, retrospective data in patients with HER2-amplified breast cancer revealed that patients with truncated p95HER2 were less responsive to HER2 therapy with trastuzumab [32] . Consistent with these mechanisms of trastuzumab resistance being active in USC, our group has recently demonstrated that p95HER2 shedding commonly occurs in vitro and in vivo in patients harboring USC with HER2/neu amplification [33] . The release of free floating receptor from the tumor surface competes for trastuzumab and decreases the bioavailability for cell membrane-associated tumor receptors. Importantly, the small tyrosine kinase inhibitor, dacomitinib, may potentially circumvent these problems, and preclinical data in breast cancer lends support to this notion. Indeed, dacomitinib molecular design allows it to bind in the ATP pocket of the ErbB1 and ErbB2 receptor-associated tyrosine kinase through the targeting of a cysteine residue [34] . This residue is conserved between these two receptors, which gives the dacomitinib shared specificity [35] . Thus, inhibition of these receptors through an irreversible covalent modification of the intracellular ATP pocket may provide more robust antitumor effects compared to trastuzumab in HER2/neu-amplified uterine serous carcinoma. Consistent with this view, our experimental results suggest that dacomitinib is remarkably active against primary HER2-amplified uterine serous carcinoma cell lines. Indeed, our in vitro results exposing multiple fully sequenced primary USC cell lines with or without c-erbB2 gene amplifications to dacomitinib clearly demonstrated a dramatic (i.e., about 100-fold difference in IC 50 ) higher sensitivity of the HER2/neu-amplified USC to the exposure of the irreversible HER2/neu inhibitor. Moreover, HER2/neu-amplified uterine serous carcinomas treated with dacomitinib showed significant inhibition of HER2 autophosphorylation and a significant decrease in the phosphorylation of the transcription factor S6. These changes in cell signaling, related to the inhibition of the tumor driver pathway HER2/neu, confer a significant build up in the G0/G1 phase of the cell cycle. Cell cycle arrest in G1 leads to decreased proliferation and is likely to lead to apoptosis. Our results in primary USC cell lines are similar to data published in preclinical studies using dacomitinib against HER2-amplified breast cancer [36] and lung cancer cell lines [37] . Phase I clinical trials in cancer patients based on the aforementioned preclinical data demonstrated dacomitinib to be generally safe and well tolerated at the maximum dose of 45 mg daily in humans. In these studies showing encouraging signs of antitumor activity in gefitinib/erlotinib-treated NSCLC patients [21] , the dose-limiting toxicities included stomatitis and skin toxicities while the most common adverse events were mild and mainly related to skin toxicities, fatigue, and gastrointestinal side effects including diarrhea, nausea, and vomiting. Data from a randomized phase II study of dacomitinib showed that, compared with the reversible EGFR inhibitor erlotinib, dacomitinib demonstrated significantly improved median progression-free survival (PFS) from 1.91 months treated with erlotinib to 2.86 months in patients with advanced non-small cell lung cancer (NSCLC) [20] . Skin effect and diarrhea were again the most prominent adverse events, and such events were mild or moderate in severity and manageable. In conclusion, the novel preclinical data presented in this study suggests that dacomitinib is endowed with remarkable activity against HER2-amplified USC in vitro and, accordingly, it may represent a novel treatment option for a significant subset of USC patients with disease resistant to chemotherapy. Phase II studies with dacomitinib in USC overexpressing HER2/neu are warranted.
